• Molecular NameZafirlukast
  • Synonymzafirlukast
  • Weight575.686
  • Drugbank_IDDB00549
  • ACS_NO107753-78-6
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)5.51
  • pkaN/A
  • LogD (pH=7, predicted)2.48
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-5.43
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors2
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds9
  • TPSA124.11
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyOral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator.
  • Absorption_valueN/A
  • Absorption (description)Rapidly absorbed following oral administration, reduced following a high-fat or high-protein meal.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding99.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP2C9-mediated)
  • Half life10 h
  • ExcretionBiliary
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include rash and upset stomach.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A